N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016

  • ID: 3753834
  • Report
  • 35 pages
  • Global Markets Direct
1 of 5
N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016

Summary

‘N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016’, provides in depth analysis on N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted pipeline therapeutics.

The report provides comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
- The report reviews N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) Overview

Therapeutics Development

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Stage of Development

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Therapy Area

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Indication

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Products Glance

Early Stage Products

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Companies

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Universities/Institutes

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Molecule Type

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Company

CohBar, Inc.

Polyphor Ltd.

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles

Drugs to Agonize FPR-2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Humanin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCP-70X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Alzheimer's Disease and Type II Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize FPR1/2 for Immunology and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize FPR1/2 for Immunology and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Projects

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Featured News & Press Releases

May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by CohBar, Inc., H1 2016

Pipeline by Polyphor Ltd., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Bristol-Myers Squibb Company
CohBar, Inc.
Polyphor Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll